Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade

Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade

Nobuhiro Hata,1,2 Koji Yoshimoto,1 Ryusuke Hatae,1 Daisuke Kuga,1 Yojiro Akagi,1 Satoshi O Suzuki,3 Toru Iwaki,3 Tadahisa Shono,1,4 Masahiro Mizoguchi,1,5 Koji Iihara1 1Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 2Department of Neurosurgery, Clinical Research...

Full description

Bibliographic Details
Main Authors: Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Suzuki SO, Iwaki T, Shono T, Mizoguchi M, Iihara K
Format: Article
Language:English
Published: Dove Medical Press 2016-11-01
Series:OncoTargets and Therapy
Subjects:
oligodendroglioma
IDH
PAV
1p19q codel
Online Access:https://www.dovepress.com/deferred-radiotherapy-and-upfront-procarbazinendashacnundashvincristin-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/deferred-radiotherapy-and-upfront-procarbazinendashacnundashvincristin-peer-reviewed-article-OTT

Similar Items